A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial
Related Posts
Sidhu N, Le BM, Doan EL, Dao KT, Montana W. A Case of Gastrointestinal Krukenberg Tumor Initially Suspected as Primary Ovarian Cancer and the Implications[...]
Bondariyan N, Patel M, Shah P, Park D, Dermarderosian A, Arfaie S, Mashayekhi M, Dashtipour K, Akhtari M. Choreiform Movements and Pachymeningeal Enhancement in an[...]
Damron LF, Kinney L, Kathuria-Prakash N, Iliopoulos M, Stefanoudakis D, Lopez LP, Sakkal M, Khanlou N, Hart SD, Moatamed NA, Palaskas NJ, Drakaki A. A[...]